Revumenib 25 mg, 110 mg, 160 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg, 110 mg, 160 mg
Reference Brands: Revuforj (USA)
Category: Oncology Cancer Care
Revumenib is a Oncology Cancer Care product available as Tablets in strengths 25 mg, 110 mg, 160 mg. It corresponds to the reference brand Revuforj (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.
Manufacture or export Revumenib? List it or send an offer →
Product Description:
Revumenib is an oral targeted anticancer medication used for the treatment of acute leukemias with lysine methyltransferase 2A (KMT2A) gene rearrangements and is marketed under the brand name Revuforj. It is specifically indicated for patients whose cancers harbor KMT2A translocations, which are known to drive aggressive leukemia progression.
Revumenib works as a menin inhibitor, disrupting the interaction between the menin protein and KMT2A (also called MLL). This interaction is critical for the survival and proliferation of leukemia cells in patients with KMT2A-rearranged acute leukemia. By blocking this pathway, revumenib helps to slow or halt cancer cell growth, providing a precision oncology approach for patients with genetically defined leukemias.
Administered orally as a film-coated tablet, revumenib offers a convenient dosing option while targeting the molecular drivers of the disease. It is generally used under medical supervision, with prior genetic testing to confirm the presence of KMT2A gene rearrangements. Revumenib represents an important therapeutic option for patients with difficult-to-treat, relapsed, or refractory acute leukemias driven by specific genetic abnormalities.
How Revumenib is supplied today, and licensing ahead of patent expiry
Where revumenib is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Revuforj · FDA · Nov 2024 |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
Revumenib is used for the treatment of relapsed or refractory acute leukemia with KMT2A gene translocations and relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation in adults and pediatric patients aged 1 year and older, whose cancers have specific genetic alterations.
Revumenib is a synthetically manufactured small-molecule menin inhibitor designed to block the interaction between menin proteins and oncogenic gene complexes in leukemia cells.
The trade name of Revumenib is Revuforj.
Revumenib (Revuforj) is developed and marketed by Syndax Pharmaceuticals, Inc.
The generic name of Revumenib is revumenib.
The brand name of Revumenib is Revuforj.
Revumenib oral tablets are manufactured in GMP-compliant pharmaceutical facilities, primarily in the USA, for global distribution.
Revuforj (Revumenib) is developed and sold by Syndax Pharmaceuticals. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.
Related Products
Selpercatinib
Strength:
40 mg, 80 mg, 160 mg
Form: Capsules
Reference Brands: Retevmo (USA)
View Details
Entrectinib
Strength:
100 mg, 200 mg
Form: Capsules
Reference Brands: Rozlytrek (USA/EU)
View Details
Temsirolimus
Strength:
25 mg/ml, 100 mg
Form: Injection
Reference Brands: Torisel (USA)
View Details
Thiotepa
Strength:
15 mg, 100 mg
Form: Injection
Reference Brands: Thioplex (USA/EU) , Tepylute (USA)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit
